Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

August 31, 2017

Conditions
Nocturia
Interventions
DRUG

Fedovapagon 2 mg

One daily dose of 2 mg fedovapagon for 12 weeks

DRUG

Placebo

One daily dose of placebo (matched to fedovapagon) for 12 weeks

Trial Locations (48)

Unknown

Vantia Investigative Center, Anniston

Vantia Investigative Center, Goodyear

Vantia Investigative Center, Lincoln

Vantia Investigative Center, Murrieta

Vantia Investigative Center, San Diego

Vantia Investigative Center, Aventura

Vantia Investigative Center, Bradenton

Vantia Investigative Center, Clearwater

Vantia Investigative Center, Coral Gables

Vantia Investigative Center, DeLand

Vantia Investigative Center, Hialeah

Vantia Investigative Center, Miami

Vantia Investigative Center, Ocala

Vantia Investigative Center, Pembroke Pines

Vantia Investigative Center, St. Petersburg

Vantia Investigative Center, Tampa

Vantia Investigative Center, Avon

Vantia Investigative Center, Topeka

Vantia Investigative Center, Wichita

Vantia Investigative Center, Greenbelt

Vantia Investigative Center, Missoula

Vantia Investigative Center, Omaha

Vantia Investigative Center, Englewood

Vantia Investigative Center, Lawrenceville

Vantia Investigative Center, Albuquerque

Vantia Investigative Center, Garden City

Vantia Investigative Center, New York

Vantia Investigative Center, Newburgh

Vantia Investigative Center, Poughkeepsie

Vantia Investigative Center, Cary

Vantia Investigative Center, Concord

Vantia Investigative Center, High Point

Vantia Investigative Center, Raleigh

Vantia Investigative Center, Wilmington

Vantia Investigative Center, Winston-Salem

Vantia Investigative Center, Akron

Vantia Investigative Center, Warwick

Vantia Investigative Center, Charleston

Vantia Investigative Center, Greer

Vantia Investigative Center, Mt. Pleasant

Vantia Investigative Center, Bristol

Vantia Investigative Center, Dallas

Vantia Investigative Center, Houston

Vantia Investigative Center, San Antonio

Vantia Investigative Center, Clinton

Vantia Investigative Center, Ogden

Vantia Investigative Center, Salt Lake City

Vantia Investigative Center, Richmond

All Listed Sponsors
lead

Vantia Ltd

INDUSTRY

NCT02637960 - Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) | Biotech Hunter | Biotech Hunter